Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer

BACKGROUND: As the implementation of trastuzumab, several studies have investigated new agents and regimens to treat human epidermal growth factor 2-positive (HER2+) metastatic breast cancer (MBC). However, long-term survival analyses from HER2-targeted therapies are lacking. This is a 20-year follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez Marti, Juan Luis, Nasrazadani, Azadeh, Ding, Ying, Normolle, Daniel, Brufsky, Adam M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628556/
https://www.ncbi.nlm.nih.gov/pubmed/37725049
http://dx.doi.org/10.1093/oncolo/oyad258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628556/
https://www.ncbi.nlm.nih.gov/pubmed/37725049
http://dx.doi.org/10.1093/oncolo/oyad258

Ejemplares similares